Genmab Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Genmab de 21.7% y 15.3% por año respectivamente. Se prevé que el BPA crezca en un 19.5% al año. Se espera que la rentabilidad financiera sea de 18.1% en 3 años.

Información clave

20.4%

Tasa de crecimiento de los beneficios

18.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.2%
Tasa de crecimiento de los ingresos	14.9%
Rentabilidad financiera futura	17.3%
Cobertura de analistas	Good
Última actualización	14 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Previsiones de crecimiento de beneficios e ingresos

CPSE:GMAB - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	28,310	8,345	8,693	9,398	16
12/31/2025	23,621	6,630	6,015	7,123	24
12/31/2024	19,801	4,683	7,663	6,401	25
3/31/2024	17,783	5,467	5,358	5,658	N/A
12/31/2023	16,474	4,352	7,004	7,380	N/A
9/30/2023	17,023	4,296	5,687	6,106	N/A
6/30/2023	16,366	4,749	5,634	6,037	N/A
3/31/2023	15,330	5,283	6,196	6,560	N/A
12/31/2022	14,505	5,452	3,595	3,912	N/A
9/30/2022	11,987	5,654	3,480	3,755	N/A
6/30/2022	10,210	3,962	1,964	2,234	N/A
3/31/2022	9,020	2,377	1,349	1,630	N/A
12/31/2021	8,417	2,957	1,976	2,228	N/A
9/30/2021	7,907	2,873	947	1,189	N/A
6/30/2021	7,321	2,513	5,609	5,820	N/A
3/31/2021	10,800	5,585	5,427	5,704	N/A
12/31/2020	10,111	4,758	6,126	6,433	N/A
9/30/2020	11,028	5,649	7,128	7,406	N/A
6/30/2020	10,344	5,656	2,369	2,647	N/A
3/31/2020	5,667	2,363	2,444	2,592	N/A
12/31/2019	5,366	2,166	1,215	1,326	N/A
9/30/2019	3,641	1,528	1,252	1,355	N/A
6/30/2019	3,199	1,170	782	1,248	N/A
3/31/2019	2,935	1,345	729	1,199	N/A
12/31/2018	3,025	1,472	537	1,015	N/A
9/30/2018	2,807	1,424	583	1,062	N/A
6/30/2018	2,532	1,239	796	892	N/A
3/31/2018	2,796	1,286	1,188	1,301	N/A
12/31/2017	2,365	1,104	N/A	1,589	N/A
9/30/2017	2,275	1,159	N/A	1,260	N/A
6/30/2017	2,316	1,354	N/A	1,422	N/A
3/31/2017	1,897	1,215	N/A	1,088	N/A
12/31/2016	1,816	1,187	N/A	328	N/A
9/30/2016	1,463	735	N/A	658	N/A
6/30/2016	1,376	686	N/A	591	N/A
3/31/2016	1,196	535	N/A	358	N/A
12/31/2015	1,133	764	N/A	311	N/A
9/30/2015	774	443	N/A	70	N/A
6/30/2015	768	463	N/A	23	N/A
3/31/2015	710	420	N/A	98	N/A
12/31/2014	850	301	N/A	133	N/A
9/30/2014	851	292	N/A	110	N/A
6/30/2014	729	138	N/A	-31	N/A
3/31/2014	751	138	N/A	-108	N/A
12/31/2013	664	70	N/A	-128	N/A
9/30/2013	611	-5	N/A	-150	N/A
6/30/2013	577	-55	N/A	152	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.7% al año) de GMAB es superior a la tasa de ahorro (0.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.7% al año) de GMAB crezcan más rápidamente que el mercado Danish (13.3% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GMAB crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.3% al año) de GMAB crezcan más rápidamente que los del mercado Danish (11.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.3% al año) de GMAB crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GMAB sea baja dentro de 3 años (18.1%).

Genmab Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 11%

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Provides Earnings Guidance for 2023

Consensus EPS estimates increase by 45%

Genmab Provides Earnings Guidance for Year 2022

Recent updates

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Consensus EPS estimates increase by 45%

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento